Can I take Asiminib without chemotherapy?

Asciminib is a new type of BCR-ABL1tyrosine kinase inhibitor (TKI), mainly used to treat chronic myeloid leukemia (CML), especially patients who are resistant or intolerant to other TKI drugs. Compared with traditional chemotherapy, Aceminib is a targeted drug that prevents the proliferation of leukemia cells by specifically inhibiting the activity of BCR-ABL1 enzyme. Therefore, many patients can be treated with aceminib alone without traditional chemotherapy.

For most patients with chronic myelogenous leukemia, targeted drug therapy is the standard treatment, and chemotherapy is not necessary. Especially for patients in the chronic phase, the use of aceminib and otherTKIdrugs is often sufficient to control disease progression without the need for concurrent chemotherapy. By precisely targeting the BCR-ABL1 fusion protein in leukemia cells, Aceminib can effectively prevent the growth and spread of cancer cells. Compared with traditional chemotherapy, it causes less damage to normal cells and therefore has milder side effects.

Chemotherapy is generally considered a systemic treatment that kills rapidly dividing cells, but it is not as precise as targeted drugs in distinguishing between cancer cells and normal cells. As a result, chemotherapy often comes with more serious side effects, such as immune system suppression, nausea, vomiting, and hair loss. Targeted drugs such as Aceminib are more selective and specifically target the genetic mutations that cause leukemia without affecting the proliferation of normal cells.

However, whether chemotherapy is completely unnecessary depends on the patient's specific condition. If patients are in the blast crisis or accelerated phase of CML, they may need a combination of chemotherapy and targeted therapy to more effectively control the disease. In this case, chemotherapy can quickly reduce the number of cancer cells, while targeted drugs are used to maintain long-term disease control.